Merrimack Pharmaceuticals

Last updated
Merrimack Pharmaceuticals, Inc.
Company type Public
Nasdaq: MACK
Russell Microcap Index component
IndustryPharmaceuticals
Founded2000;24 years ago (2000) in Cambridge, Massachusetts
Headquarters
Cambridge, Massachusetts
,
United States
Number of employees
426 (2016)
Website merrimack.com

Merrimack Pharmaceuticals, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer.

Contents

Merrimack's first FDA-approved drug was approved in 2015; Onivyde, a liposome encapsulated version of irinotecan is used for treating pancreatic adenocarcinoma. It was approved for use in the European Union the following year. [1] [2]

History

Merrimack was founded by a group of scientists from MIT and Harvard University in 2000. [3]

In 2016, Merrimack had 426 full-time employees, 103 of which had an MD or PhD. [3]

In October 2016, CEO Robert Mulroy resigned and the company announced they would be laying off 20% of its employees. [4] In January 2017, interim CEO Gary Crocker resigned and the board of directors appointed Richard Peters to be president and CEO. Peters previously worked at Sanofi and was a faculty member at Harvard University. [5]

In January 2017, French pharmaceutical company Ipsen announced they would be purchasing Onivyde from Merrimack for approximately $1 billion. [6] Following the close of the deal with Ipsen, Merrimack reduced its headcount by about 80%. By May of 2019, Merrimack planned to lay off its entire staff, including the leadership team. [7]

On November 13, 2018, the statistical programming director Songjiang Wang, received "six months in prison and one year supervised released" after a guilty verdict was handed down to Wang from a United States District Judge in July 2018 for securities fraud and conspiracy to commit securities fraud. [8] Also on December 20, 2019, the United States Securities and Exchange Commission charged Wang with Insider trading. [9]

On May 10, 2024, Merrimack announced that the stockholders at a Special Meeting held that day approved the adoption of a Plan of Dissolution. The Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share, expected to be paid on or about May 17, 2024. Merrimack’s Common Stock would continue to trade on NASDAQ through May 17, 2024 and thereafter delist from NASDAQ on May 20, 2024. [10]

Pipeline

Merrimack has four drugs in clinical development.

Related Research Articles

ImClone Systems LLC was a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and had its corporate headquarters in Bridgewater, New Jersey, and its research headquarters in New York City. On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully-owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL. Imclone lost its separate identity in 2014 when its former ImClone research and manufacturing sites were renamed Eli Lilly and Company.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.

<span class="mw-page-title-main">Pertuzumab</span> Pharmaceutical drug

Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.

Lucatumumab is a human monoclonal antibody against CD40 development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma.

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US.

MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

<span class="mw-page-title-main">Acorda Therapeutics</span> American biotechnology company

Acorda Therapeutics, Inc. is an American biotechnology company based in Pearl River, New York. The company develops therapies that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija and Ampyra (dalfampridine) in the United States.

<span class="mw-page-title-main">Incyte</span> American pharmaceutical company

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

<span class="mw-page-title-main">AbbVie</span> American pharmaceutical company

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

Seribantumab is a monoclonal antibody designed for the treatment of cancer. It binds to extracellular domain of HER3 blocking NRG1 binding and thereby preventing the activation of the receptor.

MM-151 is an oligoclonal mixture of fully human monoclonal antibodies, which binds multiple parts of the EGFR molecule It has started clinical trials in patients with RAS wild-type colorectal cancers (CRCs) that were resistant to other anti-EGFR therapies. It is intended to overcome the problem of cancers becoming resistant to monoclonal antibody therapies.

<span class="mw-page-title-main">Tonix Pharmaceuticals</span> Commercial pharmaceutical company

Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.

Istiratumab (MM-141) is an experimental monoclonal antibody for the treatment of cancer. It is a bispecific antibody targeting IGF-1R and ErbB3.

Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences.

<span class="mw-page-title-main">Deruxtecan</span> Chemical compound

Deruxtecan is a chemical compound and a derivative of exatecan that acts as topoisomerase I inhibitor.

References

  1. ↑ "Investors - Merrimack".
  2. ↑ "Onivyde pegylated liposomal EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 19 June 2020.
  3. 1 2 "Merrimack - Annual Report". Archived from the original on 2017-02-03. Retrieved 2017-02-02.
  4. ↑ Jamerson, Joshua (3 October 2016). "Merrimack Pharmaceuticals Cuts Jobs; CEO Resigns Amid Restructuring Effort". Wall Street Journal.
  5. ↑ "Merrimack - Current Report". Archived from the original on 2017-02-03. Retrieved 2017-02-02.
  6. ↑ "Ipsen to buy some Merrimack assets for about $1 billion". Reuters. 9 January 2017.
  7. ↑ "Merrimack to Lay Off Remaining Execs and Staff, Sell Assets". BioSpace. 2019-05-31. Retrieved 2024-10-22.
  8. ↑ "Former Biopharma Statistical Programmer Sentenced for Insider Trading". United States Department of Justice . November 13, 2018. Retrieved December 20, 2019.
  9. ↑ "Former Biopharmaceutical Executive Charged with Insider Trading". U.S. Securities and Exchange Commission . December 20, 2019. Retrieved December 20, 2019.
  10. ↑ "Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock". May 10, 2024. Retrieved October 22, 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.